ICLUSIG (ponatinib) efficacy

Ponatinib efficacy in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) 
and chronic phase chronic myeloid leukemia (CP-CML)

Pivotal ponatinib efficacy data from three trials—PhALLCON, OPTIC, and PACE—spanning newly diagnosed Ph+ ALL and intolerant or T315I-positive CP-CML and Ph+ ALL.1-4

ICLUSIG is supported by an established dataset. The program spans: PhALLCON, the first head-to-head phase 3 clinical trial vs another TKI in adults with newly diagnosed Ph+ ALL; OPTIC in CP-CML; and PACE in Ph+ ALL and CML.1-4 Together, these trials provide more than 5 years of efficacy follow-up in CP-CML and pivotal frontline data in Ph+ ALL.3,4  

Ph+ ALL.

In newly diagnosed Ph+ ALL, the PhALLCON trial established ICLUSIG + chemotherapy as the only FDA-approved regimen with data showing superior efficacy and comparable safety vs imatinib + chemotherapy. In relapsed or refractory Ph+ ALL, the PACE trial supports ICLUSIG for patients who are resistant or intolerant to prior TKI therapy, including those with the T315I mutation.1,2

CP-CML.

In CP-CML, ICLUSIG efficacy is supported by OPTIC, which established a response-based dose-reduction strategy that optimizes the benefit-risk balance in patients resistant to at least 2 prior TKIs or with the T315I mutation. PACE complements this with long-term follow-up demonstrating durable responses in heavily pretreated patients.1,3,4

CP-CML = chronic-phase chronic myeloid leukemia; FDA = US Food and Drug Administration; Ph+ ALL = Philadelphia chromosome-positive acute lymphoblastic leukemia; TKI = tyrosine kinase inhibitor

ICLUSIG safety profile in Ph+ ALL

ICLUSIG safety profile in CP-CML